Загрузка...
A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer
LESSONS LEARNED: This phase I study evaluated the maximum tolerated dose, dose-limiting toxicities, safety, pharmacokinetics, and efficacy of icotinib with a starting dose of 250 mg in pretreated, advanced non-small cell lung cancer patients. We observed a maximum tolerated dose of 500 mg with a fav...
Сохранить в:
| Опубликовано в: : | Oncologist |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AlphaMed Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5189627/ https://ncbi.nlm.nih.gov/pubmed/27789778 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0256 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|